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Abstract—A multifaceted strategy using a composite of anti-
cancer nanotherapeutic and natural biomaterials silk ﬁbroin
(SF) and chitosan (CS) blend scaffolds was investigated for
the treatment of a tissue defect post-tumor resection by
providing local release of the therapeutic and ﬁlling of the
defect site with the regenerative bioscaffolds. The scaffold-
emodin nanoparticle composites were fabricated and charac-
terized for drug entrapment and release, mechanical strength,
and efﬁcacy against GILM2 breast cancer cells in vitro and in
vivo in a rat tumor model. Emodin nanoparticles were
embedded in SF and SFCS scaffolds and the amount of
emodin entrapment was a function of the scaffold composi-
tion and emodin loading concentration. In vitro, there was a
burst release of emodin from all scaffolds during the ﬁrst
2 days though it was detected even after 24 days. Increase in
emodin concentration in the scaffolds decreased the overall
elastic modulus and ultimate tensile strength of the scaffolds.
After 6 weeks of in vivo implantation, the cell density
(p<0.05) and percent degradation (p<0.01) within the
remodeled no emodin SFCS scaffold was signiﬁcantly higher
than the emodin loaded SFCS scaffolds, although there was
no signiﬁcant difference in the amount of collagen deposition
in the regenerated SFCS scaffold. The presence and release of
emodin from the SFCS scaffolds inhibited the integration of
SFCS into the adjacent tumor due to the formation of an
interfacial barrier of connective tissue that was lacking in
emodin-free SFCS scaffolds. While nosigniﬁcant difference in
tumor size was observed between the in vivo tested groups,
tumors treated with emodin loaded SFCS scaffolds had
decreased presence and size and similar regeneration of new
tissue as compared to no emodin SFCS scaffolds.
Keywords—Silk ﬁbroin, Emodin, Scaffold, Breast cancer
cells, Tissue regeneration.
INTRODUCTION
Local recurrence in 2–7.5% of breast cancers post-
mastectomy defects is attributed to inadequate resec-
tion of tumor, undetected multifocal tumor, and lack of
post-surgical radiation therapy.
14 In addition, local
recurrence is shown to be present exactly at the initial
location of the primary tumor and found to be the ﬁrst
site of therapeutic failure.
19,28 To overcome these
issues, we developed the dual therapy approach by
embedding an anti-cancer drug into a biodegradable
tissue-regenerative scaffold in order to treat the mas-
tectomy defect site (Fig. 1a). While the drug inhibits the
proliferation of tumor cells, the scaffold ﬁlls the defect
after tumor removal and supports the regeneration of
local tissue within its controlled microenvironment.
Natural biodegradable polymers, silk ﬁbroin (SF)
and chitosan (CS), were chosen to mimic the extra-
cellular matrix (ECM) and to regenerate the native
tissue similar to regeneration of other tissue types.
3,8,27
SF protein polymer is derived from the silkworm
Bombyx mori and is ﬁbrous, highly permeable to
oxygen and water, exhibits high strength with ﬂexibil-
ity, has relatively low thrombogenicity, low inﬂam-
matory response, and supports cell adhesion and
growth.
2,13 CS is a deacetylated product of chitin and
provides good wound healing properties, compress-
ibility, and water storage capacity.
22,30 Three-dimen-
sional (3D) scaffolds comprising of various fractions of
SF and CS were prepared and their structural and
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2374mechanical properties were examined previously.
13
The SFCS scaffold was shown to support the regen-
eration of abdominal wall musculofascial defect,
8 for-
mation of critical-sized bone in an in vivo sheep
model,
27 and the wound healing of a dermal wound
using stem cells.
3
Scaﬀolds composed of either SF
33 or CS
17 and
embedded with microparticles have been reported to be
used for the delivery of biological agents. SF spheres
31,34
andCSmicrocapsules
1have alsobeenusedpreviouslyas
drug carriers. Collagen-CS scaffolds loaded with angio-
geninweredevelopedinordertopromoteangiogenesisin
artiﬁcialdermis.
29A liposomalCSscaffold/humanﬁbrin
gel composite system was studied for the delivery of low-
molecular weight hydrophilic drugs such as Tiroﬁban.
32
Similar studies involving SF-derived curcumin nanopar-
ticles have been conducted in order to provide long-term
therapy against cancerous cells.
12
In this study, anti-cancer drug ‘emodin’ was chosen
as a therapeutic since it blocks phosphorylation of
Her2/neu, which is over-expressed in many breast
cancers.
5,36 Emodin has shown impressive activity with
low toxicity in vivo.
36,37 Recent study has also shown
emodin-induced apoptosis in BCap-37 breast cancer
cells through mitochondrial signaling pathway.
15
We have previously shown the fabrication and
characterization of SF-derived liposomal emodin.
5,10
These particles were shown to exhibit high efﬁcacy
against Her2/neu over-expressing breast cancer cells
due to targeting of multiple pathways.
5,10 Since lipo-
somes promote site-speciﬁc delivery with controlled
and sustained release,
16,25 emodin-loaded liposomes
were entrapped within SFCS scaffold for this study. It
was hypothesized that the liposomal emodin-loaded
SFCS scaffolds when combined with a tissue ﬂap as a
composite would deliver anti-tumor therapy and
reconstructs the mastectomy defect site simultaneously.
In this study, emodin-loaded liposomal nanoparti-
cles were embedded in various blends of SF and CS
scaﬀolds and characterized. Drug entrapment, release,
and eﬃcacy against breast cancer cells were analyzed
in vitro. Efﬁcacy of the emodin-loaded scaffolds was
evaluated in an in vivo rat breast cancer model, where
emodin-loaded SFCS scaffolds and a tissue ﬂap were
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FIGURE 1. (a) A schematic of the cross-section of silk ﬁbroin and chitosan blend (SFCS)–emodin nanoparticle–latissimus dorsi
muscle (LDM) ﬂap composite applied at the tumor resected breast tissue site for the delivery of a nanotherapeutic to treat residual
tumor overlaying the normal breast tissue and reconstruct the defect site with the SFCS scaffold via the process of tissue
regeneration. (b) SFCS scaffold (25:75 blend) loaded with emodin in a circular petri dish mold (average diameter: 2.6 6 0.1 cm and
thickness: 1.3 6 0.04 mm). (c) At the time of treatment of the tumor resected breast tissue site, emodin-loaded SFCS scaffold was
sutured on the underside of the LDM ﬂap. (d) Wound closures after scaffold–nanoparticle–ﬂap composite implantation at the tumor
bearing breast tissue site.
Drug–Scaffold Composite for Cancer Therapy 2375used to reconstruct the resected defect. Scaffold deg-
radation, regeneration of new tissue, and tumor size
were evaluated as end points at 6 weeks. Overall, the
efﬁcacy of locally delivered emodin and the regenera-
tion/reconstruction with the SFCS scaffold of the
resected tumor defect site was shown to be an effective
treatment modality.
MATERIALS AND METHODS
Preparation of Emodin-Loaded Liposomal
Nanoparticles
Emodin (Sigma-Aldrich, St. Louis, MO) was
weighed and dissolved in t-butanol at 1 mg/mL as
described before.
10 1,2-Dimyristoyl-sn-glycero-3-
phosphocholine (DMPC, Avanti Polar Lipids Inc.,
Alabaster, AL) was separately dissolved in t-butanol at
5 mg/mL and 5% of Tween 20 solution (10% v/v
prepared in t-butanol) was added to DMPC solution.
Emodin and DMPC solutions were then mixed
together, frozen at 280 C overnight and lyophilized.
Dried DMPC and emodin mixture was suspended in
phosphate buffer saline (PBS) at 2.86 mg/mL emodin
concentration and mixed gently. Then, the emodin-
loaded liposomes were sonicated using water sonicator
(70 W, 42 kHz, Branson Ultrasonic Co., Danbury,
CT) for various times (5, 30, and 60 min). Sonication
was used to reduce the liposome size
24 and to enhance
the emodin entrapment.
Entrapment eﬃciency of emodin within liposomes
was calculated by centrifuging liposomal emodin
solution for 5 min at 1000 rpm.
18 The pellet containing
the free emodin was collected and the absorbance at
442 nm was measured using UV Spectrophotometer
(ThermoSpectronics, Rochester, NY).
Dynamic Light Scattering (DLS)
The liposome size was analyzed using DLS. The
measurements were performed on a Brookhaven
Instruments Inc. 90 plus Particle Size Analyzer
(Brookhaven Instruments Inc., Holtsville, NY). The
emodin-loaded liposome particles were dispersed in
ﬁltered PBS buﬀer and volume based analysis was
performed in duplicates for 2 min each to measure the
mean diameter.
Preparation of Scaﬀolds with Entrapped Liposomal
Emodin
The preparation of SF solution and its blend
with CS has been described previously.
9 Brieﬂy,
raw silk (Sao Paulo, Brazil) was degummed in 0.25%
(w/v) sodium carbonate and 0.25% (w/v) sodium
dodecylsulfate (Sigma-Aldrich) for 1 h at 100 Ct o
remove the sericin. The dried silk 10% (w/v) was dis-
solved in calcium nitrate tetrahydrate and methanol
solution (molar ratio of 1:4:2 Ca:H2O:MeOH) at
65 C. In order to make SFCS blends, CS was
dissolved in 2% acetic acid and added to the SF in
different proportions of SF and CS at 75:25, 50:50, and
25:75% (v/v). Pure SF solution and SFCS solution
were dialyzed against deionized water.
Emodin-loaded liposomes were prepared as above
after sonication for 5 min. Three diﬀerent amounts of
emodin-loaded liposomal nanoparticles (1.7, 2.8, and
4.0 mg emodin content) were mixed with 5 mL of
SFCS blend solution or pure SF solution. The mixture
was then poured into 35 9 10 mm petri dishes, frozen
overnight at 280 C, and lyophilized for 3 days. The
dry scaﬀolds were then crystallized with 4 mL of 50:50
methanol:1 N sodium hydroxide solution to crystallize
SF and to neutralize the pH of the acidic CS. The
samples with pure SF were crystallized with 50:50
methanol:water. Before characterization, the scaﬀolds
(Fig. 1b) were washed three times with PBS to remove
excess methanol and sodium hydroxide, then sterilized
in ethanol overnight, and again washed three times
with PBS to remove the ethanol.
Emodin Entrapment and Release from Scaﬀolds
The entrapment of emodin in the ﬁnal scaﬀold was
calculated by subtracting the amount of released
emodin during the crystallization, sterilization, and
PBS washing steps. The released emodin contents were
analyzed by measuring absorbance at 442 nm.
To measure the emodin release, small punches
(6 mm diameter) of the emodin-loaded scaﬀold were
placed in 1 mL of PBS in a 1.5 mL centrifuge tube at
37 C incubator shaker. The absorbance was measured
at diﬀerent time points up to 24 days to analyze the
released emodin.
Mechanical Testing
Uniaxial tensile test was performed using Endura-
TEC mechanical tester (Bose, Eden Prairie, MN). The
circular scaﬀold samples were ﬁrst trimmed to a more
rectangular shape and cut into three strips before being
tested with a 225 N load cell at a strain rate of 0.1 mm
per second. The stress–strain data were collected to
calculate the elastic modulus (EM) and ultimate tensile
strength (UTS).
Scanning Electron Microscopy
The scaﬀolds were ﬁxed in 2% paraformaldehyde
and 3% glutaraldehyde solution and imaged using
GUPTA et al. 2376JSM-590 scanning electron microscope (JEOL, USA,
Inc., Peabody, MA) as described previously.
30 Brieﬂy,
the samples were treated with a series of buffers,
coated with aluminum alloy and imaged at an accel-
erating voltage of 5 kV. The SEM images were later
analyzed using ImageJ software.
Cell Culture
Breast cancer cell line GILM2 was obtained from
lung metastasis and developed in the laboratory of
Dr. Janet Price at The University of Texas M. D.
Anderson Cancer Center.
21 The cells were cultured
in Dulbecco Modiﬁed Eagles Medium with F-12
(Invitrogen, Grand Island, NY) and supplemented
with 10% fetal bovine serum (Atlanta Biologicals,
Lawrenceville, GA) and 1% antibiotics (Invitrogen).
MTT Assay for Cell Viability
Breast cancer cells were cultured in 96-well plates at
5000 cells per well overnight. Emodin at various con-
centrations (20–100 lM) was suspended in the culture
medium and added to the cell-seeded wells. Also, the
emodin-loaded scaffolds (4.0 mg emodin) and SFCS
control scaffolds 6 mm (diameter) punches and placed
in the wells. Large amounts of culture medium
(300 lL) were used in the wells so that the scaffold
would ﬂoat and minimize cell suffocation at the bot-
tom of the well. After 4 days of incubation, the Cell
Quanti-MTT cell viability assay kit (BioAssay Sys-
tems, Hayward, CA) was used to determine the via-
bility of cells remaining in each well. Brieﬂy, 15 lLo f
MTT reagent was added to 80 lL of culture medium in
each well. After 4 h of incubation, MTT solubilization
solution (100 lL) was added to each well and plates
were placed on a shaker for 1 h. The absorbance was
then measured at 570 nm using MRX Microplate
Reader (Dynex Technologies, Guernsey, Channel
Islands, Great Britain).
In Vivo Implantation of Scaffold Composite
Nude rats underwent surgical manipulations with
the approval of the Institutional Animal Care and Use
Committee (IACUC) at The University of Texas M. D.
Anderson Cancer Center. Human breast cancer cell
lines GILM2 were injected into the L4 mammary fat
pad of nude rats (200–300 g) to develop tumors. The
tumor from a single rat was transferred to more rats
when tumor mass grew over 50 mm
3 based on the
ellipsoid volume calculation
7 in order to expand the
number of tumor bearing rats. At the time of tissue ﬂap
composite reconstruction surgery, most of the tumor
volume of 50 mm
3 was resected and a volume of
10 mm
3 remained for treatment with emodin eluting
tissue ﬂap composite. Animals were divided in three
groups as reconstruction involved ﬂap tissue only
(7 rats), SFCS scaffold (8 rats), and emodin-loaded
SFCS scaffold (8 rats). Nude rats were anesthetized
with isoﬂurane (0.5%) and oxygen (2 L/min) by mask.
The animal was placed on a rubber heating pad and
normal body temperature maintained at 37 C. The
latissimus dorsi muscle ﬂap (LDMF) that is commonly
used to cover the wound in breast tumor reconstruction
was raised from the back of the rats and placed over the
resected breast tumor site with the SFCS scaffolds (with
or without emodin) sutured and sandwiched between
the LDMF and the tumor site (Fig. 1c). The surgical
site was closed and animals were secured in their cages
under normal conditions until harvest (Fig. 1d).
Histological Examination
After 6 weeks the animals were euthanized by an
overdoseofisoﬂurane.Thereconstructedsitecontaining
the tissue ﬂap–SFCS therapeutic composite and the
underlying breast tissue were excised and harvested for
histological examination. The excised tissue was cut in
2–6 parallel sections and ﬁxed in 10% formalin,
embedded in paraﬃn and sectioned (4–6 lm thickness).
The sections were stained with hematoxylin–eosin
(H&E) to assess scaffold degradation, tumor presence,
andcellularanalysis.Thesampleswerealsostainedwith
Movatpentachrome,whichstainedcellnucleiandelastic
ﬁbers as black, collagen as yellow, muscle as red and
glycosaminoglycans as blue color. All the stained sec-
tions wereexaminedundera light microscope (Olympus
1X70, Olympus, Center Valley, PA) and imaged using a
coloredCCDcamera(Retiga4000R,QImaging,Surrey,
Canada). Images were later analyzed in the ImageJ
software to calculate the cell number and the area of
tumor, scaffold, and collagen in a tissue section.
Statistical Analysis
ThedatawerecomparedstatisticallyusingGraphPad
Instat 3 program and signiﬁcance level was chosen as
p<0.05. Also, one-way ANOVA with post hoc Tukey
test was performed for pair-wise comparisons. All data
was represented as mean ± standard error of mean.
RESULTS
Eﬀect of Sonication on Liposome Size
and Emodin Entrapment
The size of the liposomes with no sonication showed
a biomodal distribution, where 11% of the total frac-
tion was between 131 and 150 nm (134 ± 5 nm) size
Drug–Scaffold Composite for Cancer Therapy 2377and 89% between 361 and 435 nm (397 ± 13 nm) size
as shown by the size distribution (Fig. 2a). After son-
ication of 5 min, the biomodal distribution remained
although the size was signiﬁcantly (p<0.001) reduced
to 79% of the total liposomal fraction between 31 and
44 nm (37 ± 3 nm) and the remaining at 302 ± 24 nm
(Fig. 2b). Increasing the sonication time beyond 5 min
did not decrease the liposomal size any further
(Fig. 2c).
Characteristics of Liposomal Emodin-Loaded Scaﬀolds
Three diﬀerent concentrations of emodin (1.7, 2.8,
and 4.0 mg emodin/scaﬀold) were used to prepare the
emodin-loaded SFCS and SF scaﬀolds. While the
medium emodin loading concentration of 2.8 mg was
used based on previously developed formulation of
liposomal emodin that showed high eﬃcacy against
breast cancer cells,
16 the concentration of 1.7 and
4.0 mg were studied as lower and upper limits for drug
loading in order to minimize fragility of the SF based
scaffolds and maximize emodin entrapment. The
diameter and the thickness of all the scaffolds were
fairly consistent among the different blends. The
average diameter of emodin-loaded scaffold was
2.6 ± 0.1 cm and thickness was 1.3 ± 0.04 mm
(Fig. 1b).
Emodin Entrapment and Release from Scaﬀolds
The emodin entrapment within liposomes was sig-
niﬁcantly higher (p<0.01) after sonication (>99%)
compared to no sonication (83.2 ± 4.9%) as shown in
Fig. 3a. The entrapment efﬁciency of 100% suggests
that there was no free emodin in the suspension. There
was no difference in entrapment efﬁciencies with var-
ious sonication times. Emodin entrapment efﬁciencies
were found to be the highest for SF (80–87%) as
compared to the three SFCS blends (42–55%) as
shown in Fig. 3b. Absolute emodin entrapment in SF
scaffolds signiﬁcantly increased with initial loading
concentration (4.0 mg>2.8 mg>1.7 mg), although
percent (%) entrapment efﬁciency (measured with
respect to the initial emodin loading concentration)
decreased with increased initial loading concentration
(Fig. 3c). Percent emodin entrapment efﬁciency was
signiﬁcantly less (p<0.05) for 4.0 mg initial loading
concentration vs. the 1.7 mg concentration. For all
three emodin loading concentrations, addition of CS
(25–75%) to the SF based scaffolds signiﬁcantly
reduced the % entrapment efﬁciency and the amount
of absolute emodin loading in the SFCS scaffolds as
compared to the same emodin concentration in pure
SF scaffolds. For all three SFCS blends, increase in
absolute emodin loading concentration from 1.7 to
4.0 mg increased the amount of loaded drug signiﬁ-
cantly as evidenced by statistically signiﬁcant differ-
ences between 1.7 mg concentration and 4.0 mg
concentration, though there was no difference in %
emodin entrapment efﬁciency due to initial emodin
loading concentrations within the SFCS blends.
While there was a burst release of emodin from
scaﬀolds during the ﬁrst 2 days (Fig. 4), released
emodin amounts were detected (0.1–1.0 lg/mL) even
after 24 days. SF scaffolds showed highest emodin
release as compared to all SFCS blends (only 25:75
SFCS is shown in Figs. 4a, 4b). However, there was no
difference in release between various blends for the
same starting emodin concentration (data not shown).
As shown in Fig. 4b for 25:75 SFCS, % emodin release
was slightly higher for lower starting emodin concen-
tration (1.7 mg) than higher concentrations (2.8 and
4.0 mg). However, the absolute amount of emodin
release increased with an increase in starting emodin
concentration (lowest for 1.7 mg and highest for
4.0 mg emodin). Similar trends were found for other
SFCS blends and pure SF.
Mechanical Strength of Liposomal
Emodin-Loaded Scaﬀolds
Representative stress vs. strain curves are shown for
no emodin SF, no emodin 25:75 SFCS, and 1.7 mg
emodin 25:75 SFCS (Fig. 5a). The EM and the UTS
for all scaffolds with and without emodin were calcu-
lated from stress–strain curves. As shown in Fig. 5b,
the elastic moduli of the SFCS controls (no emodin)
were signiﬁcantly lower than the SF control (no emo-
din) (p<0.001). Addition of emodin to SF scaffolds
for all concentrations reduced the EM signiﬁcantly
(p<0.01). SFCS scaffolds for all three blends with
4.0 mg of emodin had signiﬁcantly lower EM (p<0.05
for 75:25 SFCS, p<0.01 for 50:50 SFCS, and 25:75
SFCS) as compared to no emodin SFCS controls for
their respective blends. While 75:25 SFCS scaffolds
showed signiﬁcantly lower EM vs. no emodin controls
only at 2.8 and 4.0 mg (p<0.05 for both) concentra-
tions, 25:75 SFCS showed signiﬁcantly lower EM for
all three emodin loading concentrations.
Increase in emodin loading concentration resulted
in signiﬁcant decrease in UTS for SF scaﬀolds
(p<0.001) (Fig. 5c). The addition of 25% CS to
pure SF control scaffolds appeared to decrease the
UTS, although not signiﬁcantly. On the other hand,
increasing the amount of CS from 25 to 75% increased
the UTS (p<0.05), while showing no signiﬁcant dif-
ference from the pure SF no emodin control scaffolds.
Increase in emodin loading concentration had no effect
on the UTS of 75:25 SFCS, signiﬁcantly decreased the
UTS for 50:50 SFCS only at 2.8 and 4.0 mg emodin
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FIGURE 2. The size of the emodin-loaded liposomes was measured using dynamic light scattering. (a) The volume based size
distribution of the emodin-loaded liposomes without sonication results in higher frequency of particles in >360 nm range.
(b) Sonication of liposomal emodin after 5 min of sonication results in higher frequency of nanoparticles ranging in size from 30 to
45 nm. (c) Mean diameter of liposomal emodin after sonication of 5 min decreased and the size was not affected by further
exposure to sonication up to 60 min.
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FIGURE 3. Emodin loading efﬁciency within the liposomes and embedding within the SF and SFCS scaffold blend formulations.
(a) Entrapment efﬁciency of emodin within the DMPC liposomes increased after sonication of 5 min and remained at 100%
efﬁciency with increased sonication time n 5 3, *p<0.01 vs. all other sonication times. (b) Absolute emodin entrapment within the
liposomal nanoparticles embedded in SF and SFCS scaffold blends (n 5 3). *p<0.001 vs. SF, 4.0 mg emodin,
up<0.001 vs. SF,
2.8 mg emodin,
ap<0.05 vs. SF, 1.7 mg emodin,
bp<0.001 vs. SF, 2.8 mg emodin,
#p<0.001 vs. SF, 4.0 mg,
p<0.05 vs. 75:25
SFCS, 4.0 mg emodin,
p<0.05 vs. 50:50 SFCS, 4.0 mg emodin,
hp<0.01 vs. 25:75 SFCS, 4.0 mg emodin, emodin. (c) Percent
entrapment of emodin within the liposomal nanoparticles embedded in SF and SFCS scaffold blends n 5 3, *p<0.05, **p<0.01 vs.
SF, 1.7 mg emodin,
p<0.001 vs. SF, 2.8 mg emodin,
hp<0.001 vs. SF, 4.0 mg emodin. All data reported as mean 6 SEM.
GUPTA et al. 2380concentrations, and decreased UTS for 25:75 SFCS at
all emodin loading concentrations as compared to the
respective no emodin blend controls (Fig. 5c). In
addition, the UTS of SF scaffolds was lower than 25:75
SFCS scaffolds at 4.0 mg emodin loading concentra-
tion (p<0.01).
Eﬃcacy of Emodin Against GILM2 Breast Cancer Cells
Emodin dose dependant eﬀects were tested in cell
culture and the cell numbers were calculated from a
standard curve between cell concentration and ﬂuo-
rescence readings using MTT assay. With no exposure
to emodin, the number of GILM2 cells increased from
5000 to 12,000–18,000 per well by 4 days and were
signiﬁcantly (p<0.001) higher than emodin exposed
cells (Fig. 6a). As the emodin exposure concentration
was increased from 20 to 100 lM, the cancer cell via-
bility decreased signiﬁcantly (p<0.05). There was a
dose dependant effect of emodin on GILM2 breast
cancer cell efﬁcacy.
GILM2 breast cancer cell eﬃcacy was also evalu-
ated using 4.0 mg emodin 25:75 SFCS scaﬀolds
(Fig. 6b). Exposure of GILM2 cells to emodin-loaded
SFCS scaffolds signiﬁcantly decreased the number of
viable cells as compared to cells in culture dishes (no
SFCS, no emodin, p<0.01) and cells exposed to SFCS
scaffolds only (no emodin p<0.05).
In Vivo Efﬁcacy of LDMF–Emodin SFCS Composite
The LDM ﬂap tissue used for reconstruction in the
in vivo model was divided into three layers: skin, con-
nective tissue, and muscle (Figs. 7a, 7b). The tumor
showed distinguished dense tissue with a very high
concentration of cells, which interfaced with the mus-
cle tissue ﬂap, in the case of ﬂap reconstruction only.
At 6 weeks, the defect reconstruction with SFCS
scaffold only (no emodin) resulted in the residual
SFCS scaffold seamlessly integrating adjacent to the
muscle site (Fig. 7b) and the tumor site (Fig. 7c),
whereas the emodin-loaded SFCS scaffold appeared to
integrate with a distinct interface between the tumor
and the regenerated scaffold tissue (Fig. 7d). The
tumor appeared to be isolated yet connected with the
emodin-loaded SFCS scaffold via a new tissue inter-
face. The release of emodin from the SFCS appears to
block the tumor invasion into the neighboring regen-
erated SFCS scaffold. Both scaffolds integrated well at
the muscle tissue ﬂap interface evidenced by invasion
of cells from the muscle and formation of new blood
vessels (see arrows at the interface) at the interface
(Fig. 7e). By 6 weeks, remodeling and regeneration of
the SFCS scaffold was evidenced by cellular inﬁltration
and new matrix deposition in both scaffold groups
(Fig. 7f). Deposition of new matrix was evidenced by
areas of deep yellow positive staining for collagen and
light blue staining for glycosaminoglycans in regions of
remodeling scaffold (Figs. 7e, 7f). The degraded
scaffold ﬁbrils were dispersed throughout the remod-
eled/regenerated tissue and stained in shades of red/
magenta with H&E/Movat staining, respectively.
Quantiﬁcation of In Vivo Therapeutic
and Remodeling Response
Histological sections with H&E staining were eval-
uated for quantiﬁcation of tumor presence and relative
tumor size. Fewer slides (25%) showed tumor in the
emodin-loaded SFCS scaﬀold group compared to
ﬂap only (40%) and SFCS scaﬀold only (33%) group.
Although, no signiﬁcant diﬀerence was observed in
tumor size between groups, the emodin-loaded SFCS
scaﬀold group showed decreased tumor presence and
size (Table 1). Tumor was evident in 25% of the
emodin-loaded SFCS scaffolds and the size of these
tumors was slightly smaller than the SFCS scaffold
only group.
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pared within the groups (Table 1). The cell density in
the remodeled SFCS scaffold (3238 ± 152 cells/mm
2)
was signiﬁcantly higher (p<0.05) than the emodin-
loaded SFCS scaffold (2733 ± 118 cells/mm
2). There
was no signiﬁcant difference between the two SFCS
scaffold groups in the amount of area occupied by
newly deposited collagen. Scaffold degradation was
quantiﬁed by processing original images as shown
in Fig. 8. By 6 weeks, scaffold degradation in the
emodin-loaded SFCS scaffold (87.6 ± 2.1%) was
signiﬁcantly (p<0.01) less than no emodin SFCS
scaffold (94.3 ± 0.8%).
DISCUSSION
The emodin-loaded SFCS scaﬀold composite was
designed for the treatment of breast tissue defects that
occur due to tumor resection. In the in vitro part of this
study, the composite was successfully prepared by
embedding emodin nanoparticles within various blends
of SF and CS scaffolds. Emodin entrapment was a
function of initial emodin loading concentration and
the SF to CS blend ratios which also affected the
overall mechanical properties of the resultant scaf-
folds. The efﬁcacy of emodin-loaded SFCS scaffold
composites was tested in vitro and in an in vivo rat
GILM2 breast tumor model, which showed an effect
on the wound healing response of the tumor with and
without emodin-loaded SFCS scaffolds and regenera-
tion of the defect site with the SFCS scaffold.
The liposomal encapsulation of emodin has been
previously developed by our group and thus served as
a starting point for embedding emodin in the SFCS
scaﬀolds.
5,10 Initially, the entrapment of emodin within
the SFCS scaffolds was tested without liposomal
encapsulation, although the entire drug washed out in
the crystallization and sterilization steps. The hydro-
phobic nature of emodin and its afﬁnity towards
organic solvents results in the drug leaching out during
the crystallization and sterilization steps. Therefore,
the emodin-loaded SFCS scaffolds consisted of lipo-
somal emodin rather than free emodin embedded in
the SFCS matrix.
The process of sonication was performed to reduce
the liposomal emodin size to less than 100 nm
24 and to
enhance the entrapment of emodin within the lipo-
somes. The sonication of only 5 min was sufﬁcient to
decrease the average liposome size (<100 nm) and to
enhance the emodin entrapment within liposomes.
Entrapment signiﬁcantly improved by sonication that
generated smaller liposomes with higher surface area.
Although, sonication signiﬁcantly reduced the average
size of the liposomal emodin, a small amount of par-
ticles in the 200–300 nm range could have affected the
reduction in tensile strength observed for SF and SFCS
blends with increasing emodin loading concentration.
Once encapsulated within the SF or SFCS scaffolds,
the nanoparticles were visible on the surface of the
scaffold. Similar observation of thin SF layer on
PLGA microparticles embedded in SF scaffolds has
been observed previously.
33
Final emodin entrapment within the scaﬀolds was
signiﬁcantly higher for pure SF compared to all SFCS
blends although there was no diﬀerence between
SFCS blends, which indicates that CS does not favor
the entrapment of liposomal emodin. CS at biologi-
cally relevant pHs holds an inherently negative charge
due to the lone pair of electrons on the free amines
11
and this may result in lower entrapment of hydro-
phobic emodin as compared to SF and its blends,
where the hydrophobic peptides such as alanine and
glycine that form the crystalline core of SF may have
facilitated the higher entrapment of hydrophobic
emodin, especially in pure SF scaffolds. Regardless,
the SFCS scaffolds were able to retain 42–55% of
initial emodin loading concentration. The higher
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FIGURE 6. (a) Cell viability of GILM2 breast cancer cells
measured using the MTT assay after 4 days of exposure to
liposomal emodin nanoparticles. The increase in the emodin
concentration decreased the number of viable cells (n 5 3),
#p<0.001 vs. control,
p<0.05 vs. 20 lM emodin concentra-
tion. (b) Comparison of GILM2 breast cancer cell viability after
exposure to liposomal emodin 25:75 SFCS, 4.0 mg emodin
scaffolds with no emodin controls with and without the 25:75
SFCS scaffold (n 5 3), *p<0.01 vs. control,
p<0.05 vs. SFCS
only. All data reported as mean 6 SEM.
Drug–Scaffold Composite for Cancer Therapy 2383FIGURE 7. Histological microsections of the reconstructed GILM2 breast tumor site after 6 weeks of implantation of 25:75 SFCS-
emodin nanoparticle-muscle ﬂap composite stained with either H&E or Movat stains. (a) A Movat stained cross-section of the
breast tumor site reconstructed with the LD muscle tissue ﬂap only. (b) A H&E stained cross-section of the tumor site recon-
structed with the SFCS scaffold shows the muscle ﬂap components (skin, connective tissue, muscle) interfaced and well-
integrated with the partially degraded emodin-loaded SFCS scaffold that contains the interspersed ﬁbrils embedded in the
regenerated tissue. (c) A H&E stained cross-section of tumor scaffold interface that was seamlessly integrated when reconstructed
with SFCS scaffold-LDM ﬂap composite with no emodin loading. (d) A Movat stained cross-section of remodeled emodin-loaded
SFCS scaffold interfaced with a tumor via layers of connective tissue. (e) A Movat stained cross-section showing the blood vessels
(see arrows) formed at the interface of the muscle and the emodin loaded SFCS scaffold. (f) A Movat stained cross-section of the
SFCS scaffold showing partial degradation and remodeling of the scaffold. The remainder scaffold ﬁbrils (red) are surrounded by
collagen (yellow) deposited in the regenerated tissue.
GUPTA et al. 2384starting emodin concentrations resulted in higher
entrapped emodin for all SFCS blends.
Percent emodin release was higher for pure SF than
SFCS blends, which may be a function of higher initial
entrapment of emodin in SF vs. SFCS. Under in vitro
conditions, the emodin release was slow from the
scaffolds because of the barriers of the liposomal wall
and the scaffold that emodin would have to extravasate
during release. The release process would be facilitated
in vivo by the wound healing microenvironment that
results in the degradation of the scaffold with time. The
release mechanism of emodin from SF-coated lipo-
somes has been described previously as diffusion lim-
ited.
10 It may be speculated that the emodin release
from SFCS scaffolds is primarily diffusion controlled
similar to previously reported curcumin release from
SFCS particles.
12 Nevertheless, under in vivo condi-
tions, the actual release rates are also a function of the
amount of degradation of the scaffolds with time. The
in vivo release of emodin from the liposomes in SFCS
scaffolds is synergistically facilitated by diffusion and
degradation of SFCS with time.
Emodin inhibited the growth of GILM2 cells in a
dose-dependent manner as the highest dose (100 lM)
caused minimum cell viability after 4 days of incuba-
tion. Previous studies have shown the emodin dose-
dependent inhibition of BCap-37 breast cancer cells
with 50% inhibition at 50 lM concentration by 48 h
and 90% inhibition of MDA-MB 453 cells at 40 lM
concentration with SF coated emodin-loaded lipo-
somes.
5,15 Emodin has been shown to cause breast
cancer cell apoptosis through Her2/neu pathway
5,36 or
Bcl-2 mediated mitochondrial pathway.
15 However,
apoptosis of other cancer cells upon emodin exposure
targeted other pathways such as caspase-3 cascade in
promyeleukemic HL60 cells,
6 JAK2/STAT3 pathway
in myeloma cells,
26 Bax and Fas pathway in lung car-
cinoma CH27 cells.
20 Thus, there may be many possible
mechanisms of GILM2 cell apoptosis upon exposure to
emodin that were not investigated as part of this study.
In vivo implantation of emodin-loaded SFCS scaf-
folds resulted in integration at the tumor site via a
connective tissue interface, reduced cell density, and
slower degradation compared to SFCS scaffold only
TABLE 1. Quantitative analysis of tumor size, scaffold degradation and cell density in the tissues after 6 weeks of in vivo
implantation.
Groups
Tumor presence
based on slide
Tumor size per
microsection (mm
2)
Cell density
in scaffolds
Collagen in remodeling
scaffold (%)
Scaffold
degradation (%)
Flap only 40% (6/15) 1.02 ± 0.43 na na na
SFCS scaffold only 33% (7/21) 1.47 ± 0.46 3238 ± 152 (n = 23) 9.0 ± 1.8 (n = 6) 94.3 ± 0.8 (n = 30)
Emodin-loaded SFCS
scaffold
25% (5/20) 0.97 ± 0.57 2733 ± 118
 (n = 28) 7.8 ± 1.5 (n = 10) 87.6 ± 2.1* (n = 25)
*p<0.01 and
p<0.05 vs. SFCS scaffold only.
FIGURE 8. The degradation of SFCS scaffold was quantiﬁed using image processing in Image J software. An example of the
(a) original H&E image and (b) the image after processing shows the area covered by non-degraded scaffold.
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folds may have been due to the emodin release
resulting in tumor cell apoptosis and inhibiting further
tumor cell invasion of the remodeling SFCS scaffold.
Overall reduction in cellular extravasation thus
resulted in lower degradation of the scaffold and
reduced integration with the surrounding tumor. Local
delivery of a therapeutic via a poly(ester-carbonate)-
collagen composite for the treatment of lung cancer
has been reported to show higher efﬁcacy in terms of
lowering local recurrence as compared to intravenous
administration of the therapeutic.
35 In this study, the
presence of tumor was low in the emodin-loaded SFCS
group but there was no signiﬁcant difference in the
tumor size as compared to no emodin SFCS and ﬂap
only controls. While most rats had reduced tumor size,
one of the rats in the emodin-loaded scaffold group
had comparatively larger tumor residue that resulted in
higher standard error and reduced statistical signiﬁ-
cance.
The presence of blood vessels and collagen within
the SFCS scaﬀold after 6 weeks of implantation is
evidence of the regenerative potential of the SFCS
scaﬀolds regardless of the presence of the drug. Pre-
vious studies have shown tissue regeneration with
SFCS scaﬀold in abdominal wall musculofascial repair
model,
8 bone regeneration model,
27 and a wound
healing model.
3
In conclusion, liposomal emodin-loaded 25:75
SFCS scaﬀold composites were successfully prepared
with good mechanical integrity, optimal drug entrap-
ment and release over time, and reduced breast cancer
cell viability in vitro. In the in vivo breast tumor model,
the composite with entrapped drug resulted in reduced
tumor presence, scaffold degradation, remodeling, and
new tissue deposition. The drug loaded scaffold com-
posite for cancer therapy and tissue regeneration has
great promise for reconstruction of tumor defects in
order to prevent recurrence and encourage long-term
healing. SFCS composite has the ﬂexibility for incor-
porating versatile therapeutics for the treatment of
various tumors
4,23 and guiding cellular response
towards regeneration by incorporating small mole-
cules/therapeutics, such as siRNA,
4 for local delivery.
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